Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia

Pain

Volumn 139, Issue 1, 2008, Pages 190-200

  Mallet, Christophe ^a,b   Daulhac, Laurence ^a,b   Bonnefont, Jérôme ^a,b   Ledent, Catherine ^c   Etienne, Monique ^a,b   Chapuy, Eric ^a,b   Libert, Frédéric ^a,b,d   Eschalier, Alain ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Acetaminophen; Endocannabinoids; Fatty acid amide hydrolase; Nociception; Serotonin

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ARACHIDONYL 2' CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FATTY ACID AMIDASE; PARACETAMOL; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; MALE; MECHANICAL STIMULATION; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SPRAGUE DAWLEY RAT; THERMAL STIMULATION;

ACETAMINOPHEN; ANALGESIA; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; MALE; MICE; MICE, KNOCKOUT; PAIN; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 51749108193     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.03.030     Document Type: Article

References (54)

1. Alloui A., Chassaing C., Schmidt J., Ardid D., Dubray C., Cloarec A., et al. Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats. Eur J Pharmacol 443 (2002) 71-77
2. Bardin L., Lavarenne J., and Eschalier A. Serotonin receptor subtypes involved in the spinal antinociceptive effect of 5-HT in rats. Pain 86 (2000) 11-18
3. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
4. Bjorkman R., Hallman K.M., Hedner J., Hedner T., and Henning M. Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain 57 (1994) 259-264
5. Bonnefont J., Alloui A., Chapuy E., Clottes E., and Eschalier A. Orally administered paracetamol does not act locally in the rat formalin test: evidence for a supraspinal, serotonin-dependent antinociceptive mechanism. Anesthesiology 99 (2003) 976-981
6. Bonnefont J., Chapuy E., Clottes E., Alloui A., and Eschalier A. Spinal 5-HT1A receptors differentially influence nociceptive processing according to the nature of the noxious stimulus in rats: effect of WAY-100635 on the antinociceptive activities of paracetamol, venlafaxine and 5-HT. Pain 114 (2005) 482-490
7. Compton D.R., and Martin B.R. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 283 (1997) 1138-1143
8. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265 (1993) 218-226
9. Conti S., Costa B., Colleoni M., Parolaro D., and Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135 (2002) 181-187
10. Costa B., Siniscalco D., Trovato A.E., Comelli F., Sotgiu M.L., Colleoni M., et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 148 (2006) 1022-1032
11. Courade J.P., Chassaing C., Bardin L., Alloui A., and Eschalier A. 5-HT receptor subtypes involved in the spinal antinociceptive effect of acetaminophen in rats. Eur J Pharmacol 432 (2001) 1-7
12. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
13. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., et al. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281 (2001) 444-451
14. Di Marzo V., and Deutsch D.G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5 (1998) 386-404
15. Fowler C.J., Stenstrom A., and Tiger G. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Pharmacol Toxicol 80 (1997) 103-107
16. Fox A., and Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs 14 (2005) 695-703
17. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92 (2001) 91-100
18. Fride E., and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231 (1993) 313-314
19. Giuffrida A., Beltramo M., and Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298 (2001) 7-14
20. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., and Deutsch D.G. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100 (2003) 4269-4274
21. Guhring H., Hamza M., Sergejeva M., Ates M., Kotalla C.E., Ledent C., et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 454 (2002) 153-163
22. Haller V.L., Cichewicz D.L., and Welch S.P. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546 (2006) 60-68
23. Högestätt E.D., Jonsson B.A., Ermund A., Andersson D.A., Bjork H., Alexander J.P., et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280 (2005) 31405-31412
24. Hohmann A.G., and Suplita Jr. R.L. Endocannabinoid mechanisms of pain modulation. Aaps J 8 (2006) E693-E708
25. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
26. Kikkawa R., Fujikawa M., Yamamoto T., Hamada Y., Yamada H., and Horii I. In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J Toxicol Sci 31 (2006) 23-34
27. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 317 (2006) 1365-1371
28. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
29. Lund A., Tjolsen A., and Hole K. The apparent antinociceptive effect of desipramine and zimelidine in the tail flick test in rats is mainly caused by changes in tail skin temperature. Pain 38 (1989) 65-69
30. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316 (2006) 969-982
31. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40 (1991) 471-478
32. Meng I.D., and Johansen J.P. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124 (2004) 685-693
33. Meng I.D., Manning B.H., Martin W.J., and Fields H.L. An analgesia circuit activated by cannabinoids. Nature 395 (1998) 381-383
34. Mestre C., Pelissier T., Fialip J., Wilcox G., and Eschalier A. A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 32 (1994) 197-200
35. Millan M.J. Descending control of pain. Prog Neurobiol 66 (2002) 355-474
36. Muth-Selbach U.S., Tegeder I., Brune K., and Geisslinger G. Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation. Anesthesiology 91 (1999) 231-239
37. Ottani A., Leone S., Sandrini M., Ferrari A., and Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 531 (2006) 280-281
38. Ouellet M., and Percival M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 387 (2001) 273-280
39. Pelissier T., Alloui A., Caussade F., Dubray C., Cloarec A., Lavarenne J., et al. Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. J Pharmacol Exp Ther 278 (1996) 8-14
40. Pelissier T., Alloui A., Paeile C., and Eschalier A. Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors. Neuroreport 6 (1995) 1546-1548
41. Pertwee R.G. The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol 46 (1972) 753-763
42. Pickering G., Loriot M.A., Libert F., Eschalier A., Beaune P., and Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther 79 (2006) 371-378
43. Pini L.A., Sandrini M., and Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol 308 (1996) 31-40
44. Piomelli D., Giuffrida A., Calignano A., and Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21 (2000) 218-224
45. Rinaldi-Carmona M., Calandra B., Shire D., Bouaboula M., Oustric D., Barth F., et al. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278 (1996) 871-878
46. Russo E.B., Guy G.W., and Robson P.J. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 4 (2007) 1729-1743
47. Russo R., Loverme J., La Rana G., Compton T.R., Parrott J., Duranti A., et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322 (2007) 236-242
48. Tjolsen A., Lund A., and Hole K. Antinociceptive effect of paracetamol in rats is partly dependent on spinal serotonergic systems. Eur J Pharmacol 193 (1991) 193-201
49. Vaughan C.W., Connor M., Bagley E.E., and Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57 (2000) 288-295
50. Vaughan C.W., McGregor I.S., and Christie M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127 (1999) 935-940
51. Walker J.M., and Huang S.M. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 235-242
52. Wiley J., Balster R., and Martin B. Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276 (1995) 49-54
53. Wiley J.L., and Martin B.R. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471 (2003) 185-193
54. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110